Focused On-demand Library for Cytochrome P450 2W1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TAV3

UPID:

CP2W1_HUMAN

Alternative names:

CYPIIW1

Alternative UPACC:

Q8TAV3

Background:

Cytochrome P450 2W1, known as CYPIIW1, is a pivotal enzyme in retinoid and phospholipid metabolism. It specializes in the hydroxylation of saturated carbon hydrogen bonds, including the transformation of all trans-retinoic acid to 4-hydroxyretinoate, potentially regulating its clearance. CYPIIW1 also processes various lysophospholipids and activates procarcinogens, indicating a complex role in cellular processes.

Therapeutic significance:

Understanding the role of Cytochrome P450 2W1 could open doors to potential therapeutic strategies. Its involvement in metabolizing lysophospholipids and activating procarcinogens highlights its potential impact on tumorigenesis and retinoid metabolism disorders.